Proton pump inhibitors (PPIs) are the drug of choice to prevent upper gastrointestinal (UGI) bleeding in patients receiving dual antiplatelet therapy (DAPT); however, unmet needs remain. Potassium‐competitive acid blockers (P‐CABs)… Click to show full abstract
Proton pump inhibitors (PPIs) are the drug of choice to prevent upper gastrointestinal (UGI) bleeding in patients receiving dual antiplatelet therapy (DAPT); however, unmet needs remain. Potassium‐competitive acid blockers (P‐CABs) are novel acid‐suppressive drugs that have emerged as potential alternatives. We evaluated the effectiveness of P‐CAB in reducing the risk of UGI bleeding in patients receiving DAPT after percutaneous coronary intervention (PCI).
Keywords:
bleeding;
upper gastrointestinal;
dual antiplatelet;
antiplatelet therapy;
bleeding patients;
potassium competitive
Journal Title: Journal of Gastroenterology and Hepatology
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Gastroenterology and Hepatology
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!